hPD-1/hPD-L1/HLA-A2.1/B2M
Nomenclature
C57BL/6JSmo-Pdcd1tm1(hPDCD1)Cd274tm1(hPD-L1)B2mtm1(hB2M-linker-HLA-A*0201/H2-D1)Smoc
Cat. NO.
NM-XA-252092
Strain State
Repository Live
Model Description
Validation Data
Tabel 1. Body weight and organs weight of male WT C57BL/6 mice and homozygous hPD-1/hPD-L1/HLA-A2.1/B2M mice. Values are shown as Mean±SME.
Abbr. HO, homozygous; WT, wild type.
Table 2. Blood routine examination of male homozygous hPD-1/hPD-L1/HLA-A2.1/B2M mice. Values are expressed as mean±SEM.
Abbr. HO, homozygous; WT, wild type.
Table 3. Biochemical test of serum from hPD-1/hPD-L1/HLA-A2.1/B2M mice. Values are expressed as mean±SEM.
Abbr. HO, homozygous; WT, wild type.
Fig.1 Detection of (A) myeloid cell subsets and (B) lymphocyte subsets in the blood of hPD-1/hPD-L1/HLA-A2.1/B2M knock-in mice by FACS. hPD-1/hPD-L1/HLA-A2.1/B2M knock-in mice showed a normal immune phenotype in blood.(n=4 in each group, 7-8 weeks old).
Abbr. WT, wild type; HO, homozygous.
Fig.2 Detection of (A) myeloid cell subsets and (B) lymphocyte subsets in the spleen of hPD-1/hPD-L1/HLA-A2.1/B2M knock-in mice by FACS. hPD-1/hPD-L1/HLA-A2.1/B2M knock-in mice showed a normal immune phenotype in spleen, except for a significant decreased proportion of CD8+ T cells compared to the WT mice (n=4 in each group, 7-8 weeks old).
Abbr. WT, wild type; HO, homozygous.
Fig.3 Detection of lymphocyte subsets in lymphnodes of hPD-1/hPD-L1/HLA-A2.1/B2M knock-in mice by FACS. hPD-1/hPD-L1/HLA-A2.1/B2M knock-in mice showed a normal immune phenotype in lymph nodes, except for a significant decreased proportion of CD8+ T cells compared to the WT mice (n=4 in each group, 7-8 weeks old).
Abbr. WT, wild type; HO, homozygous.
Fig.4 Pathological analysis of homozygous hPD-1/hPD-L1/HLA-A2.1/B2M knock-in mice by H＆E staining. There were no obvious pathological changes in spleen, thymus, stomach, colon, brain, heart and kidney tissues in homozygous hPD-1/hPD-L1/HLA-A2.1/B2M knock-in mice (n=3, male, 7-8 weeks old, 4x magnificantion for brain and 10x magnification for other tissues).
You may also like
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn moreMilestones
Our vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.
Learn more
